New neffy Data on Clinical Efficacy Presented at 2024 AAAAI Annual Meeting
AAAAI 2024. New data on neffy (epinephrine nasal spray) include the first report of efficacy after oral food challenge in a pediatric population at risk for anaphylaxis.
Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improved Lung Function and Asthma Control, According to New Data
AAAAI 2024. Patients with asthma who received dupilumab plus medium-dose ICS had improved lung function and asthma control vs those who received placebo plus high-dose ICS.
Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study
AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.
First Study of Oral Mucosal Immunotherapy for Peanut Allergy Elicits Robust Immunologic Response in Adults
AAAAI 2024. Oral mucosal immunotherapy delivered via metered-dose toothpaste produced a statistically significant increase in IgG4 and a decrease in IgE/IgG4 ratio.
Tezepelumab Demonstrates Sustained Post-Treatment Reductions in CSU Disease Activity, Inflammatory Markers
AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.
More Timely Care for Chronic Liver Disease is Coming, Step-by-Step, says Hepatologist Bruce Luxon, MD, PhD
Reducing stigma associated with chronic liver disease and expediting diagnosis and referral will take some time but progress is being made, Luxon says.
To Help Reduce the Burden of Chronic Liver Disease, Primary Care Needs Simple, Reliable, Available Tools
Transplant hepatologist Dr Bruce Luxon says primary care is essential to making progress against chronic liver disease but doesn't have the resources it needs.
10 Top Studies from The Liver Meeting 2023: At-a-Glance
Simplified risk stratification tools for NAFLD, effects of statins on hepatic disease, trends in OHE, and patient perspectives are samples of the noteworthy research areas.
Underestimation of OHE Hospitalizations: Author of New Study Discusses Clinical Implications, Takeaways for Primary Care Clinicians
Arun Jesudian, MD, details key findings from a study he recently presented at The Liver Meeting 2023.
Cutting Daily Sodium Intake Significantly Lowers Blood Pressure in 1 Week, According to New Research
AHA 2023: Reducing daily sodium intake by about 4000 mg significantly lowered SBP in approximately 73% of adults in 1 week when compared to a higher sodium diet.
Systolic BP Target of <120 mm Hg Reduces CV Event Risk, According to New Data from AHA Scientific Sessions 2023
AHA 2023: An intensive 3-year treatment targeting SPB <120 mm Hg resulted in 39% lower CV mortality than standard treatment in patients with HTN at high risk of CVD.
Speech May be a Promising Biomarker for MHE, OHE, According to New Research
TLM 2023: Speech analyzed from a smartphone app recording identified MHE and predicted OHE with results comparable to those from validated assessments.
How to Change the Course of Chronic Liver Disease in the US: Create a Groundswell Movement
TLM 2023: Reduce disease stigma and treatment inequality, build awareness for early diagnosis across specialties, support clinicians with accessible tools, and that's a start.
NASH Diagnosis: Patients Overwhelmed But Motivated to Adhere to Guidance and Want More Help, Survey Finds
More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.
Cloud-Based "Liver Toolkit" Identifies Primary Care Patients at High Risk for Fibrosis, Requiring Referral
One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.
FIB-4 Risk-Stratification Algorithm for MASLD Improved Primary Care Practice Patterns, According to New Research
TLM 2023: Primary care clinicians exposed to a FIB4-based risk stratification algorithm reported applying it routinely for patients with elevated LFTs after the introduction.
New Data Show Rise in Decompensated Cirrhosis and Hepatic Encephalopathy Cases among US Medicare Beneficiaries
TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.
New NAFLD Familial Risk Score Outperforms FIB-4 for Predicting Advanced Fibrosis in First-Degree Relatives
TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.
Novel Algorithm, FAST-3, Shows Promise as Noninvasive Classifier for Advanced Fibrosis in MASLD
The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.
Hepatic Steatosis is a Risk Factor for MACE, Even Among Individuals at Low 10-Year ASCVD Risk
TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.
